Two vertical-software franchises sold down on AI-disruption narratives that do not survive contact with their customers' actual workflows
Veeva Systems (VEEV) is the dominant platform for life-sciences regulatory and clinical data management. Tyler Technologies (TYL) is the dominant platform for government ERP, court management, and tax administration. Both share a common structural feature: their primary moat is not technological — it is the cost, time, and political risk of replacement.
VEEV carries higher near-term conviction on valuation re-rating potential and passive-flow catalysts (S&P 500 inclusion). The compression from ~60× to ~18× forward P/E prices in permanent TAM compression that is inconsistent with Vault's position inside GxP-regulated pharma workflows.
TYL offers a longer compounding horizon with lower near-term catalyst visibility but superior earnings durability — a ~27% EPS CAGR over five years while the stock declined ~4% annually. The thesis is not a re-rating to a growth premium; it is that at current multiples, earnings growth alone generates attractive absolute returns.
Neither name requires an AI thesis to work — both benefit from AI narratives reversing, as that removes the primary overhang in VEEV and the primary neglect in TYL. Neither position should be sized for a 6-month outcome.
| Business | Cloud software for life sciences — Vault (regulatory, clinical, quality) and Commercial Cloud (CRM, data) |
| Revenue (LTM) | ~$2.8B · ~85% subscription · ~$1.3B free cash flow |
| Forward P/E | ~18× (5-year median ~60×; discount to median ~70%) |
| Analyst consensus | ~77% upside; predominantly Buy-rated |
| S&P 500 | Included — ongoing passive inflow tailwind |
| Moat | Regulatory switching cost + vendor lock-in (Vault); competitive intensity in Commercial Cloud |
VEEV's current valuation implies permanent TAM compression — a scenario inconsistent with the structural position of Vault within GxP-regulated pharma workflows. The compression from ~60× to ~18× forward P/E is driven by three fears: (1) AI agents replacing SaaS vertical software, (2) Salesforce/ServiceNow encroachment on Commercial Cloud, and (3) a biotech capex freeze reducing expansion budgets.
Vault manages regulatory submissions (FDA, EMA, PMDA), clinical trial documentation (TMF), pharmacovigilance, and quality management across the drug-development lifecycle. These are not workflow-optimisation tools — they are regulatory record systems operating under 21 CFR Part 11, EU Annex 11, and GAMP 5.
The bear case has legitimate grounding in Commercial Cloud (~30% of revenue). Salesforce Life Sciences Cloud is a credible competitor with superior horizontal CRM capabilities. If VEEV loses share here, multiple recovery to 40×+ becomes harder to sustain on Vault alone. Primary monitoring variable: Commercial Cloud NRR and win/loss rates vs. Salesforce.
| Severity | Risk Factor | Mitigant |
|---|---|---|
| Medium | Commercial Cloud share loss to Salesforce Life Sciences | Monitor VEEV win/loss disclosures, Salesforce vertical pipeline commentary |
| Medium | Biotech spending freeze deepens — delays Vault expansion | Position sizing; revenue base is expansion-sensitive, not cancellation-sensitive |
| Low | Horizontal AI agent replacing Vault as a regulatory SoR | Revalidation obligation + 21 CFR Part 11 create barriers no current AI product addresses |
| Low | M&A by large pharma creating in-house alternative | Historical precedent non-existent; cost/complexity deters |
| Business | SaaS for state & local government — ERP, court management, tax administration, public safety, payments |
| Revenue (LTM) | ~$2.3B · ~85% recurring · ARR growing ~18% YoY |
| EPS growth (5yr) | ~27% CAGR — while the stock declined ~4% annually over the same period |
| Forward P/E | ~35× — premium to market but near multi-year lows for TYL |
| Contract profile | Multi-year (10–15yr) sole-source; procurement cycles 2–4 years |
| Moat | Procurement lock-in + legacy integration depth + political switching cost |
Tyler is a compounding machine the market persistently undervalues because it lacks a consumer-facing narrative and has zero AI-hype exposure. The 27% EPS CAGR against a flat-to-negative stock price is the most straightforward description of the opportunity: earnings have compounded aggressively while the multiple has compressed. The thesis is not that TYL re-rates to a growth premium — it is that at current multiples, earnings growth alone generates attractive absolute returns.
The 27% EPS CAGR over five years — through rising rates, austerity narratives, and multiple compression — is the most important data point in the thesis. This is not buyback-driven EPS manipulation; it reflects genuine operating leverage on a recurring base. EBITDA margins have expanded from ~22% pre-pandemic to ~35%+ as the SaaS transition reaches critical mass.
The AI-disruption case here is weaker than in virtually any vertical. Government data cannot be processed on third-party AI infrastructure without FedRAMP/StateRAMP certification — a 12–18 month process per offering. TYL builds AI-native features inside its own certified environment (Tyler AI), converting AI from a threat into an ARPU-expansion mechanism within the locked base.
The primary risk is a sustained, structural reduction in state & local government IT budgets. TYL has minimal direct federal revenue, but state block grants (ARPA, federal pass-throughs) have historically funded modernisation that drives expansion. Monitor: NASBO fiscal survey, state budget cycles, federal discretionary spending in the SLTT category.
| Severity | Risk Factor | Mitigant |
|---|---|---|
| High | Sustained reduction in state/local IT budgets driven by federal grant withdrawal | Diversification across 50 states; core renewal revenue is not grant-dependent |
| Medium | DOGE-style austerity spreads to state level; new administration freezes IT spend | TYL revenue is renewal-weighted, not new-contract-weighted; watch NASBO data |
| Low | FedRAMP-certified AI entrant (Microsoft, SAP) targets government ERP | Certification + legacy integration complexity create a multi-year entry barrier |
| Low | Organic churn from dissatisfied municipalities | Gross retention ~98%; contract structure makes mid-term exit extremely costly |
| Dimension | VEEV | TYL |
|---|---|---|
| Moat type | Regulatory compliance lock-in | Procurement + integration lock-in |
| Disruption risk | Low (Vault) · Medium (Comm. Cloud) | Very low |
| Conviction level | High | Moderate–High |
| Catalyst horizon | Near-term (re-rating, passive flows) | Long-term (compounding) |
| Earnings growth | ~17% CAGR (consensus) | ~20%+ CAGR (consensus) |
| Primary watch | Commercial Cloud NRR | Government spending trajectory |
| AI positioning | AI = feature expansion within Vault | AI = ARPU upsell within locked base |
These two positions are structurally complementary within a concentrated equity book. VEEV provides near-term re-rating optionality with a clear catalyst path; TYL provides slow-compounding earnings durability with very low correlation to technology-cycle sentiment. Neither name requires an AI thesis to work — both benefit from AI narratives reversing.
VEEV re-rating depends on macro (rates, biotech risk appetite) and on Commercial Cloud stabilisation — neither on a definable schedule. TYL compounding is definitional rather than event-driven. Neither position should be sized for a 6-month outcome.